Pharmacology, in vitro activity, and in vivo efficacy of new antifungal agents |
| |
Authors: | Nathan P Wiederhold |
| |
Institution: | (1) University of Texas Health Science Center at San Antonio, PERC MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA |
| |
Abstract: | Invasive fungal infections remain significant clinical challenges and are associated with high morbidity and mortality in
immunocompromised patients. Despite the availability of new antifungal agents, response rates against many of these infections
remain suboptimal. In addition, many of the clinically available agents have limited oral bioavailability, are associated
with adverse effects due to similarities between fungal and mammalian cells, or have significant drug-drug interactions. For
these reasons, there is great interest in developing new antifungal drugs, including those with novel mechanisms of action.
This article reviews the pharmacology, in vitro activity, and in vivo effectiveness of new antifungal agents, including members
of new classes with novel mechanisms of action and at various stages of preclinical and clinical development. These agents
include the triazole isavuconazole, the echinocandin aminocandin, the histone deacetylase inhibitor MGCD290, and the sordarin
derivative FR290581. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|